<DOC>
	<DOCNO>NCT00168740</DOCNO>
	<brief_summary>Rituximab antibody make laboratory . It bind lymphoma cell kill . Treatment recurrent B-cell lymphoma rituximab may delay prevent relapse . A total 166 patient recurrent B-cell lymphoma give intravenous rituximab week 4 week . The patient ' tumor measure treatment . Ten patient complete response 70 patient partial response rituximab . The median duration response 11.2 month .</brief_summary>
	<brief_title>Treatment Relapsed Low-Grade Follicular Lymphoma With Rituximab ( Also Known Rituxan , IDEC-C2B8 , IDEC-102 )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Diagnosis relapse , lowgrade follicular Bcell lymphoma CD20positive lymphoma Progressive , measurable disease Sign inform consent 3 week beyond standard therapy Good performance status Adequate hematologic , renal , hepatic function Chronic lymphocytic leukemia Lesions great equal 10 cm diameter CNS lymphoma AIDSrelated lymphoma Pleural effusion ascites secondary lymphoma Active , opportunistic infection Serious nonmalignant disease Prior investigational therapy , include prior antiCD20 therapy Recent major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>rituximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>B-cell lymphoma</keyword>
	<keyword>low-grade</keyword>
	<keyword>follicular</keyword>
	<keyword>anti-CD20 monoclonal antibody</keyword>
</DOC>